It has also recently been reported that empagliflozin, an inhibitor of the renal glucose cotransporter sodium glucose cotransporter 2 (SGLT2) which is an anti-diabetic drug, could be considered as an alternative therapy for neutropenia cases. This evidence concerns the gene SLC5A2 and neutropenia.